Sarissa Capital Management LP Has Decreased Its Achillion Pharmaceuticals INC (ACHN) Stake by $6.00 Million

August 8, 2018 - By Ash Ash

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) LogoInvestors sentiment decreased to 0.95 in 2018 Q1. Its down 1.13, from 2.08 in 2017Q4. It dropped, as 26 investors sold ACHN shares while 29 reduced holdings. 17 funds opened positions while 35 raised stakes. 107.48 million shares or 2.61% less from 110.36 million shares in 2017Q4 were reported. Citigroup holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 164,410 shares. 2.87M are owned by Citadel Advsrs Ltd. United Automobile Association holds 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) or 18,775 shares. Blair William & Company Il invested in 55,500 shares. D E Shaw &, New York-based fund reported 337,786 shares. Stifel Financial owns 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 401,200 shares. Spark Ltd Company reported 100,300 shares. Ameritas Invest Ptnrs holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 10,118 shares. Bancorp Of Ny Mellon reported 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Legal & General Gp Incorporated Public Ltd Com reported 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). California Employees Retirement Sys reported 0% stake. Metropolitan Life Ins holds 41,013 shares or 0% of its portfolio. Morgan Stanley stated it has 324,522 shares. Susquehanna Grp Llp holds 101,900 shares. Amalgamated National Bank reported 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Sarissa Capital Management Lp decreased its stake in Achillion Pharmaceuticals Inc (ACHN) by 80% based on its latest 2018Q1 regulatory filing with the SEC. Sarissa Capital Management Lp sold 2.00M shares as the company’s stock rose 5.28% while stock markets declined. The hedge fund held 500,000 shares of the health care company at the end of 2018Q1, valued at $1.86 million, down from 2.50 million at the end of the previous reported quarter. Sarissa Capital Management Lp who had been investing in Achillion Pharmaceuticals Inc for a number of months, seems to be less bullish one the $347.23M market cap company. The stock decreased 1.95% or $0.05 during the last trading session, reaching $2.51. About 286,885 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 13.49% since August 8, 2017 and is downtrending. It has underperformed by 26.06% the S&P500.

Analysts await Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report earnings on August, 14. They expect $-0.13 earnings per share, up 18.75 % or $0.03 from last year’s $-0.16 per share. After $-0.15 actual earnings per share reported by Achillion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -13.33 % EPS growth.

More recent Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news were published by: Nasdaq.com which released: “Achillion Reports Second Quarter 2018 Financial Results” on August 08, 2018. Also Seekingalpha.com published the news titled: “Achillion Is A Worthwhile Biotech Speculation” on July 12, 2018. Benzinga.com‘s news article titled: “Benzinga’s Biotech Pulse: Pfizer’s Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke …” with publication date: August 01, 2018 was also an interesting one.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage

Among 2 analysts covering Achillion Pharmaceuticals (NASDAQ:ACHN), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Achillion Pharmaceuticals had 2 analyst reports since February 23, 2018 according to SRatingsIntel. Barclays Capital upgraded Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) rating on Monday, May 21. Barclays Capital has “Hold” rating and $500 target. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Hold” rating by FBR Capital on Friday, February 23.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: